Axel Nielsen
Plus aucun poste en cours
Profil
Axel Nielsen has been Chief Operating Officer of deCODE genetics, Inc. since June 2007.
Previously, he was Chief Operating Officer of deCODE's US operations from June 1998 to 2002.
Mr. Nielsen was Vice President-Investor Relations, Vice President-Finance, Treasurer and Chief Financial Officer of deCODE genetics.
Before joining deCODE, he was with Icelandair, Inc. and McKinsey & Co. Mr. Nielsen received a BS degree in Computer Science and Finance from the University of Iceland and an MBA degree from MIT Sloan School of Management.
Anciens postes connus de Axel Nielsen
| Sociétés | Poste | Fin |
|---|---|---|
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Directeur des opérations | 01/01/2010 |
Formation de Axel Nielsen
| University of Iceland | Undergraduate Degree |
| Massachusetts Institute of Technology | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |